Target

DLL3

Delta-like protein 3

34open trials
44trials in total
34publications
0researchers

Diseases

The last 24 months

New trials, publications, preprints and grants on this target, month by month.

TrialsPublicationsPreprintsGrants

Trial
DLL3 CAR-T Therapy Targeting Brain Tumors
1 Jun 2027· PHASE1_PHASE2 · NOT_YET_RECRUITING· CTGOV
Trial
A Study of ZL-1310 in Combination With a Checkpoint Inhibitor Versus Standard of Care Platinum Based Chemotherapy With a Checkpoint Inhibitor as First-line Therapy in Participants With Extensive-Stage Small Cell Lung Cancer
31 Dec 2026· PHASE3 · NOT_YET_RECRUITING· CTGOV
Trial
A Study of 177Lu-DTPA-SC16.56 in People With Neuroendocrine Carcinomas of the Lung and Prostate
1 Dec 2026· PHASE1 · NOT_YET_RECRUITING· CTGOV
Trial
A Phase I Study of HS-20093 in Combination With ZG006 With or Without Adebrelimab in Patients With ES-SCLC
15 Nov 2026· PHASE1 · NOT_YET_RECRUITING· CTGOV
Publication
Cell Surface Expression and PET Imaging Establish DLL3 as a Clinically Actionable Target in Neuroblastoma.
2 Nov 2026· Journal of nuclear medicine : official publication, Society of Nuclear Medicine· PUBMED
Publication
The evolving landscape of DLL3-directed Therapeutics in small cell lung cancer.
29 Oct 2026· Cancer treatment reviews· PUBMED
Publication
Parallel 4-1BB Signaling in Dual DLL3/CD56-Targeting CAR T Cells Triggers Adaptive Proliferation and Functional Persistence to Eradicate Small Cell Lung Cancer.
15 Oct 2026· Cancer research· PUBMED
Trial
A clinical trial to learn more about the effects of DJI136 in people with extensive-stage small cell lung cancer
9 Oct 2026· PHASE1_PHASE2 · NOT_YET_RECRUITING· CTIS
Publication
Clinicopathological Features of DLL3 Expression and T-Cell Infiltration in LCNEC: Insights From Pathology and Clinical Response to Tarlatamab.
1 Oct 2026· Thoracic cancer· PUBMED
Preprint
DLL3 expression predicts response and long-term outcome in small cell lung cancer patients treated with tarlatamab.
7 Sept 2026· bioRxiv : the preprint server for biology· PUBMED
Trial
A Study of Armored CAR T Cells in People With Cancer
28 Aug 2026· PHASE1 · RECRUITING· CTGOV
Publication
DLL3 expression in neuroendocrine carcinomas: a comparative analysis across tumor origins.
12 Aug 2026· Frontiers in endocrinology· PUBMED
Trial
BL-M14D1 Plus Atezolizumab vs Standard of Care in First-Line Extensive-Stage Small Cell Lung Cancer (BrenDeLL-Lung01)
4 Aug 2026· PHASE3 · RECRUITING· CTGOV
Publication
VHH-Based CAR-T Cells Targeting DLL3 Show High Efficacy in Small Cell Lung Cancer Models.
4 Aug 2026· Molecular cancer therapeutics· PUBMED
Publication
DLL3-Targeted Strategies in Advanced Prostate Cancer: Current Evidence and Future Perspectives.
29 Jul 2026· Drugs· PUBMED
Publication
DLL3-directed immune redirection in small-cell lung cancer: a lineage-defined vulnerability that doubles as an escape route.
28 Jul 2026· Frontiers in immunology· PUBMED
Publication
The JAK1 inhibitor golidocitinib boosts therapeutic potency of DLL3-targeted CAR-T therapy for small cell lung cancer.
20 Jul 2026· Pharmacological research· PUBMED
Publication
Machine learning-driven identification of DLL3 as a molecular target and development of a DLL3-binding cyclic peptide for glioblastoma.
14 Jul 2026· Frontiers in oncology· PUBMED
Publication
Tarlatamab in Relapsed SCLC With Idiopathic Pulmonary Fibrosis: A Case With Comparative DLL3 Expression Analysis: Case Report.
14 Jul 2026· JTO clinical and research reports· PUBMED
Trial
DAREON®-NEC-1: A Study in People With Advanced Extrapulmonary Neuroendocrine Cancer (epNEC) to Compare Obrixtamig Plus Carboplatin and Etoposide Treatment With Standard Chemotherapy
10 Jul 2026· PHASE3 · RECRUITING· CTGOV
Publication
Safety and efficacy of DLL3 CAR-T cells armored with dnTGFBR2 in a subject with recurrent small-cell lung cancer: case report.
7 Jul 2026· Frontiers in oncology· PUBMED
Trial
Comparing DLL3 PET/CT to Standard Scans in Neuroendocrine Cancer
6 Jul 2026· PHASE2 · RECRUITING· CTGOV
Trial
A Study to Test How Well ZL-1310 may Work Compared to Therapies Selected by the Investigator in Treating Patients with Relapsed Small Cell Lung Cancer
26 Jun 2026· PHASE3 · RECRUITING· CTIS
Publication
Multiplexed quantitative proteomics in small-cell lung cancer: stage-linked DLL3 distribution and an independent prognostic signal of thymidine phosphorylase.
26 Jun 2026· Translational lung cancer research· PUBMED
Trial
A First-in-human (FIH), Phase 1 Study of ML261, an Autologous Potency Enhanced Anti-DLL3 CAR T Cell Therapy, in Participants With R/R SCLC or Select NECs (SPECTRAL-1)
23 Jun 2026· PHASE1 · RECRUITING· CTGOV
Trial
A Study to Evaluate DJI136, a DLL3-targeted CAR-T Therapy
16 Jun 2026· PHASE1_PHASE2 · RECRUITING· CTGOV
Trial
TC-D101 Cell Therapy for Patients With DLL3-Positive SCLC
10 Jun 2026· EARLY_PHASE1 · RECRUITING· CTGOV
Publication
DLL3 Expression in a Genotyped Cohort of Sporadic Medullary Thyroid Carcinomas.
8 Jun 2026· The American journal of surgical pathology· PUBMED
Publication
Trained immunity-primed DLL3-targeted CAR macrophages for the eradication of small cell lung cancer.
1 Jun 2026· Journal of advanced research· PUBMED
Publication
IAR025, a novel anti-DLL3 x CD3-bispecific antibody, displays high antitumor efficacy in preclinical models of small-cell lung cancer.
26 May 2026· Cancer immunology, immunotherapy : CII· PUBMED

Who works on it

Researchers who published on this target. Leave out your own co-author circle to find people you do not know yet.

No published researcher profile on this target yet.

We look for a fixed list of target names in titles, keywords, intervention names and MeSH terms. A mention does not prove that the work is aimed at that target.

Report an error